INTRODUCTION
Sudden cardiac death (SCD) is a major cause of mortality in adult congenital heart disease (ACHD) patients, and is mostly caused by ventricular arrhythmias, i.e. ventricular tachycardia (VT) or ventricular fibrillation (VF). The overall SCD incidence in the entire population of ACHD patients is low: 0.09-0.26% annually, but still manifold higher than in the age-matched population without congenital heart disease. 1, 2 Although these numbers are low due to the inclusion of many patients with low-risk lesions in these analyses, for example those with an isolated small atrial septal defect (ASD), certain individuals may be at increased risk. Ultimately, SCD accounts for 19-26% of all deaths in ACHD patients. [3] [4] [5] As more patients with congenital heart disease survive to adulthood and the population grows older as a result of improved surgical techniques, both the relative and absolute rates of SCD are expected to rise.
The implantable cardioverter-defibrillator (ICD) has been proven to effectively prevent SCD in patients with (non-)ischemic cardiomyopathy and is recommended by extensive international guidelines. [6] [7] [8] ICD's have also been shown to effectively convert life-threatening arrhythmias in ACHD patients, 9 but robust clinical evidencebased guidelines are lacking. The choice for ICD implantation in ACHD patients after resuscitated cardiac arrest may be evident. However, the indication for ICD implantation for primary prevention can be more challenging and is often based on the presence of multiple risk factors. Furthermore, as prospective evidence for ACHD patients is unavailable, indications for ICD implantation are often extrapolated from studies in patients with other cardiac conditions, retrospective data or expert opinions. To our knowledge, no systematic reviews have addressed ICD implantation in the general population of ACHD patients thus far. As no randomised clinical trials are available for ICD implantation in ACHD, such data is of paramount importance to be able to weigh benefit and risk in individual patient decision making. Therefore, we systematically reviewed the available literature on ICD indications, efficacy and ICD-related harm in ACHD patients.
This systematic review was conducted in accordance with the PRISMA guidelines. 10 Studies providing exclusive (i.e. not derived from the same cohort on which another study has also reported) and extractable data on ACHD patients with an ICD were included. Available data on ICD indication (primary or secondary prevention) was required for inclusion.
Participants in included studies were ACHD patients who underwent ICD implantation. Adult patients were defined as ≥16 years old. Finally, studies that also reported on non-ACHD patients were included only if the data from those patients was excludable from the analyses. Alternatively, when this was not possible, we incorporated studies with a minimum of 95% ACHD patients.
We included studies reporting on implantation of any type of ICD; transvenous, epicardial, subcutaneous (S-ICD) 11 or any other configuration. Likewise, we included any type of lead configuration; single-chamber, dual-chamber, cardiac resynchronisation therapy (CRT-D) or any other type of lead arrangement.
Main focus
The main focuses of this systematic review are:
1. The indication for ICD implantation; primary or secondary prevention. ICD implantation for sustained VT or for cardiac arrest/VF defined secondary prevention. ICD implantation in the absence of a secondary prevention indication defined primary prevention. 2. Appropriate ICD interventions, defined as an ICD shock or anti-tachycardia pacing (ATP) in response to proven VT or VF. 3. Inappropriate shocks, defined as an ICD shock for any other reason. 4. ICD-related complications. These were defined as generator infection, thrombotic events, lead failure and dislodgement, lead endocarditis, minor and major bleeding, cardiac perforation and pericardial effusion, pneumo-or haemothorax, unspecified re-intervention and ICD-related death.
Electronic searches
A medical librarian (J.L.) performed a comprehensive search in OVID MEDLINE, OVID EMBASE and the non-MEDLINE subset of PubMed from inception to 11 th November 2014. To avoid overlooking papers that did not mention (any) congenital heart disease or ICD in the title or abstract we also included the first 400 relevance-ranked articles found with a full-text Google Scholar search. For the MEDLINE and EMBASE search we used both index terms and text words for ICD and congenital heart disease for both general terms and specific diagnoses. Venous and coronary anomalies were not incorporated into this search. No language or other restrictions were applied. The search included an iterative process to refine the search strategy by adding search terms as new relevant citations were identified (i.e. via reference and citation checking of relevant studies in Web of Science). The bibliographic records retrieved were imported and deduplicated. The complete search strategy for MEDLINE is presented in supplementary table 1.
Data collection and analysis
Two investigators (J.V. and T.B.) independently screened for eligibility of studies. In the case that studies reported serial data on the same patient cohort and overlapping data could not be excluded, only the study that provided the largest number of patients was included. Conference abstracts of unpublished studies were only included when published less than one year before the search. Case reports and review papers were excluded.
Two investigators (J.V. and T.B.) independently extracted data. In addition to data on the main focuses we extracted data on study characteristics, patient characteristics, followup duration, electrophysiological studies (EPS), ICD and lead configuration and mortality. For one study (n=136) the patient data set was used in addition to the article to provide the most accurate and complete data. 9 Differences between reviewers regarding study selection or data extraction were resolved by consensus or by consultation of a third reviewer (J.d.G.)
To evaluate the quality and risk of bias of included studies we applied the NewcastleOttawa Quality Assessment Scale for Cohort Studies, which was accommodated to the studies included in this systematic review. 12 We performed sensitivity analyses to compare: a. studies with fewer than 50 vs. 50 or more patients, b. with the date of last inclusion before vs. after the 1 st of January 2010, c. those with or without data on follow-up duration and d. those with a higher versus a lower study quality. 
Statistical analysis
Analyses were performed using Comprehensive Meta-Analysis Version 2.2 (Biostat Inc., Englewood, NJ, USA) and Microsoft Excel 2010. For continuous data sample size weighted grand means and standard deviations of sample means (or medians, whichever was reported) were calculated. Categorical data were described in percentages. Metaanalysis was performed for the main focuses to calculate proportions and annual rates with 95% confidence intervals (CI). Random effects models (REM) weighted by inverse variance were used because of heterogeneity in the underlying cardiac pathology. Heterogeneity was assessed by calculating the Q-statistic and the I². A p-value of <0.05 for the Q-statistic was considered to be statistically significant. An I² of >40% was also considered to be an indication of substantial heterogeneity.
RESULTS

Search results
The deduplicated search yielded 1354 abstracts. After exclusion based on title and abstract, 142 full text articles were reviewed. Twenty-four observational studies (21 published studies and 3 abstracts of unpublished studies) were included. 9,13-35 Screening of reference lists of included studies and referring articles did not yield additional articles. Figure 1 shows a flowchart for selection of studies. 
Study characteristics and risk of bias
The included studies were highly variable in numbers of patients, ranging between 2 and 1683. Similarly, congenital heart defects were diverse. Seven studies included patients with one particular congenital lesion; tetralogy of Fallot (ToF) in one 23 (n=121) and transposition of the great arteries (TGA) in six 13, 16, 22, 28, 32, 35 (n=83). Appropriate and inappropriate shock rates and ICD-related complications were the most common outcomes.
All studies comprised retrospective analyses. Therefore, the study quality of most studies was low and five large studies (n=426) were of moderate quality. 9, [21] [22] [23] [24] The study quality scoring is displayed in supplementary table 2.
A recent publication on a large U.S. registry reported the number of procedures performed instead of number of patients. 20 To minimise bias and double reporting, we incorporated the data for the 1683 initial implants only. Secondly, no follow-up data was provided. Four other studies 18, 21, 32, 34 (n=86) overlapped with this study and were, therefore, only used for analyses of follow-up data.
Funnel plots did not reveal any substantial publication bias for each of the outcomes of main focus of this meta-analysis. 
Outcomes
A total of 2162 exclusive ACHD patients who underwent ICD-implantation were included from 24 studies. Supplementary table 3 displays the main outcomes of the studies. The congenital heart defects of patients are displayed in figure 2 and other characteristics of included patients are displayed in table 1.
A transvenous ICD was implanted in 96.1% of patients (0.9% epicardial, 0.2% S-ICD, remainder not specified). Of patients with a transvenous ICD 36% received a single chamber ICD, 56% a dual chamber ICD and 7% a CRT-D system (nine studies, n=243).
Holter data was available in four studies (n=299), in which Holter monitoring before ICD implantation was performed in 63% of patients, and in 33% of these patients VT's were captured.
ICD indications
Approximately half of all implantations (53.2%, 43.5-62.7) were for primary prevention indications (20 studies, n=2162, figure 3a). A total of 360 specific primary prevention indications were reported for 239 primary prevention patients (16 studies, n=430). The decision for ICD for primary prevention was commonly based on multiple risk factors (figure 3b).
No information on what combination of risk factors indicated ICD implantation was reported.
Specific indications for ICD implantation for secondary prevention in 220 patients were sustained VT in 61% and cardiac arrest in 39% (19 studies, n=473). In the sensitivity analyses there were no significant differences in the proportion of primary prevention indication. In the sensitivity analyses there were no significant differences between studies in the proportion of patients with appropriate interventions. Figure 5a shows the proportions of appropriate ICD interventions in different congenital heart defects.
Appropriate ICD interventions
In ToF patients with versus without surgical scars in one study (n=121), the hazard ratio of scars for appropriate ICD interventions was 2.5 (1.1-5.4). 23 Another study (n=59) found that ToF patients, who are more likely to have ventricular scars, had a higher rate of appropriate interventions compared to non-ToF ACHD patients: 27.3% in 2.9 years vs. 11.5% in 3.7 years (p=0.045), respectively. 21 In our pooled analysis there was no difference in appropriate intervention rates between ToF (27%) and non-ToF (25%) patients. In patients with a presumed ventricular scar (ToF, ventricular septal defect (VSD), pulmonary atresia, complete atrioventricular septal defect (AVSD), congenitally corrected TGA with VSD, double-outlet right ventricle with Rastelli surgery) 28% received appropriate ICD interventions, compared to 35% of patients without a ventricular scar (10 studies, n=181). 
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Complications and inappropriate shocks
Over one in four patients (25.6%, 18.9-33.6) experienced ICD-related complications (11 studies, n=433, figure 6a). Mean follow-up was 3.8±0.8 years (eight studies, n=424). Seventy-six per cent of complications involved lead-or generator-related issues (figure 6b).
Inappropriate shocks (16 studies, n=518) occurred in 25.2% (20.1-31.0) of patients (figure 7a). The mean follow-up was 3.7±0.8 years (12 studies, n=499). A total of 390 inappropriate shocks were delivered to 76 patients (11 studies, n=275). First inappropriate shocks were caused by supraventricular tachycardias in 68% of patients, sinus tachycardia in 17% of patients and oversensing or lead failure in 13% of patients. In the remaining 2% the reason was not specified (14 studies, n=506, of which 120 patients with inappropriate shocks).
Analyses of all complications and inappropriate shocks, including patients with multiple events are available in supplementary figure 2 and 3.
Sensitivity analyses revealed no meaningful differences between studies in the proportion of patients with inappropriate shocks or complications. 
NOS: not otherwise specified
Mortality
No ICD-related deaths were reported. Overall, 10% of patients died (15 studies, n=440). Mean follow-up was 3.7 ±0.9 years (11 studies, 404 patients). The annual death rate was 3%. SCD despite ICD implantation occurred in 18% of all deaths, heart failure in 41%, other cardiac causes in 11% and non-cardiac causes in 7%. In the remainder the cause of death was unknown (15 studies, 440 patients).
DISCUSSION
In adults with congenital heart disease who underwent ICD implantation, a remarkably high rate of appropriate ICD interventions, both in primary prevention (22% in 3.3 years) and secondary prevention (35% in 4.3 years) was found. Mortality in ACHD patients with an ICD was higher than in the average population of ACHD patients; 10% death during a mean follow-up of 3.7 years versus 3% in 3.6 years respectively, 5 most likely due to more severe heart failure and general condition. However, mortality rates were much lower than in the conventional ICD population of ischemic and non-ischemic cardiomyopathy patients of the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), where 22% of ICD recipients died during a median of 3.8 years of follow-up. 6 This may be because ACHD patients were younger at implantation (mean age 36.5 versus 60.1 years) and likely had less comorbidity. Thus, despite the notion that the appropriate shock rate in this study is similar to that in SCD-HeFT, the cumulative beneficial effect across decades is expected to be much greater in ACHD patients than in acquired heart disease, due to a more favourable appropriate intervention to mortality ratio. It is also important to note that the studies presented here included more contemporary cohorts compared to the studies in patients with acquired heart disease; those patients may currently receive less appropriate interventions as a result of improved medical therapy and advanced device programming. Therefore, it is likely that the majority of ICD implantations in ACHD patients were warranted. It may even be a sign that ICD's were only implanted in the patients at highest risk for SCD and that some individuals who may have benefited from an ICD did not receive the device.
Appropriate intervention rates were similar for most congenital diagnoses. However, a large portion of ASD and AVSD patients received appropriate interventions (figure 5a). This is likely an effect of low patient numbers (11 and 3 respectively) and selection bias, since only the patients with the highest perceived risk underwent ICD implantation. 
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ICD's were implanted for primary and secondary prevention at a roughly 50/50 ratio. Indications for primary prevention were variable and multifactorial with non-sustained VT, impaired systemic ventricular function, inducible VT and syncope being the most prevalent. Patients in whom syncope was the indication for ICD implantation received the most appropriate interventions (30%); therefore, ICD implantation in these patients was likely appropriate. Patients with non-sustained VT, inducible VT, impaired SVF and presyncope received fewer appropriate interventions (~15%). ICD implantation for these indications may, therefore, also have been appropriate, especially in the presence of several of these risk factors. Patients with palpitations, prolonged QRS or impaired subpulmonary ventricular function did not receive appropriate interventions. Hence, the latter indications may point to potentially unneeded ICD implantations. When compared to non-inducible patients, inducible VT in EP studies did not predict appropriate interventions (odds ratio 1.2 (0.2-5.7)), in contrast to what was found in another study for sustained VT or SCD in ToF patients. 36 VT ablation may have been performed in patients with inducible VT and we cannot rule out that this leads to the lower predictive value of inducible VT for appropriate ICD interventions. Although no data is available in the studies included here, VT ablation may prevent ventricular arrhythmias and shocks in ACHD patients, and requires further studying. Surgical ventricular scars are potentially an important substrate for ventricular arrhythmias. ICD implantation occurred several decades after surgical repair, which may indicate that the risk of SCD is not perceived until long after surgical repair. This emphasises the importance of follow-up after surgery and continuing attention to the risk of SCD.
The complexity of decision making underlines the importance of clear primary prevention indications. The 2015 ESC guidelines on ventricular arrhythmias and the prevention of SCD, in which the evidence for ICD implantation is derived from retrospective studies, expert opinions or extrapolation from other patient groups, confirm this. Our findings support these guidelines; the indications listed there are indeed associated with appropriate ICD interventions (figure 5b).
Aside from high appropriate intervention rates, numerous patients experienced inappropriate shocks and ICD-related complications. These rates were higher compared to SCD-HeFT (26% complications vs. 14%, both in 3.8 years). 6 Although it is reasonable to assume that a large portion of complications appear during or shortly after implantation, cumulative numbers may still be substantial.
The vast majority of complications were due to lead failure or dislodgement. There are a number of potential reasons for this high lead failure rate; lead placement can be more difficult in ACHD patients due to the complex anatomy, causing more unstable leads. AHCD patients are younger and have more active lifestyles than the much older patients with acquired heart disease. Patients may also face several generator replacements and additional cardiac surgery, which can destabilise leads. Advanced device and lead technology may substantially reduce complication rates and inappropriate shocks resulting from failed leads. The S-ICD may especially be valuable for ACHD patients, since to our knowledge no lead failures with this device have been reported thus far, with similar efficacy. Moreover, potential anatomical challenges of transvenous lead implantation in ACHD patients can be overcome with a subcutaneous approach.
Impaired ventricular sensing and high defibrillation thresholds in ACHD patients may add to inappropriate therapy, implying that involvement of an electrophysiologist with the implantation is advised. Although no data was available in these studies, advanced device programming may help reduce both appropriate and inappropriate shocks in ACHD patients.
Studies reporting solely on patients in whom an ICD was implanted only deliver limited data on the efficacy of the device. A multicentre randomised controlled trial on ICD implantation in adults with congenital heart disease is of paramount importance, although ethical and practical objections may prevent its execution. Prospective studies in which patients with risk factors for SCD are compared to patients without risk factors are an important first step towards a randomised trial. Such studies are urgently needed to fill this knowledge gap, and to prepare for the future where the number of ACHD patients will increase and their age will advance.
Limitations
All included studies were retrospective cohort studies. Lower levels of evidence and a higher risk of selection bias, incomplete outcome data and reporting bias may apply to this study design. Therefore, we grade the overall level of evidence as low to moderate, with only five studies being of moderate quality.
9,21-24 Funnel plots did not reveal any significant publication bias. There was substantial heterogeneity in patient numbers, although sensitivity analysis did not reveal significant differences in outcomes in studies with fewer or more than 50 patients. There was also heterogeneity in the types of congenital heart defects, indications and outcomes between included studies. Regional differences (USA vs. Europe/Asia) are a likely explanation for part of the heterogeneity in implantation indications. Patients with ToF and TGA account for a large portion of ICD recipients in studies with aggregate ACHD patients and several studies reported solely on patients with these diagnoses. Thus, these patients may be overrepresented in our systematic review. Primary prevention indications were often multifactorial, but in most cases reported separately. This precluded us to report on which combination of risk factors indicated ICD implantation and most often lead to appropriate interventions.
CONCLUSIONS
A remarkably high rate of appropriate ICD interventions was reported in ACHD patients with an ICD, both in secondary and primary prevention. Thus, ICD implantation based on a multifactorial decision determined by parameters derived from studies in patients with acquired heart disease and retrospective studies in ACHD patients appears adequate. Because ACHD patients were younger and death rates were much lower compared to patients with acquired heart disease, ACHD patients will likely face many more years of ICD therapy. The cumulative beneficial, but also harmful effects of the device may, therefore, be greater. Although current improvements in ICD technology may help reduce the many lead-related issues, the substantial complication and inappropriate shock rates stress careful weighing of costs and benefits per individual patient. 12 (100) 1 (8) 3 (25) 2 ( 23 (62) 5 (14) 9 (24) 14 ( 68 (56) 37 (31) 30 (25) 36 ( 14 (19) 11 (15) 11 ( ...
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